At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
adalimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)
In Brief
A Phase 4 clinical trial evaluating adalimumab for Moderate to Severe Crohn's Disease. Completed, enrolled 100 participants.
Detailed Summary
The purpose of this study is to evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Crohn's Disease
Countries--
CollaboratorsLaboratorio Echevarne, Pivotal S.L.
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartJun 2014
Primary CompletionAug 2016
Study CompletionJan 2017
TodayJul 2026
First PostedMay 28, 2014
Enrollment StartJun 1, 2014
Primary CompletionAug 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.1 years ago
Interventions
adalimumabbiological
Adalimumab pre-filled syringe, administered by subcutaneous injection